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Sudden cardiac death (SCD) due to sustained ventricular
tachyarrhythmias (VTA) remains a major public health
problem because of poor understanding of the mechanisms.
Initiation of VTA in animal models and in patients usually
requires intense metabolic or electrical stimuli not often
observed for spontaneous arrhythmias, suggesting that pro-
found but clinically silent electrophysiological changes are
responsible for lethal VTA (1). Studies performed in the
1980s and 1990s showing diurnal variations of SCD and
VTA generated excitement because they suggested that
time-varying factors participate in the initiation of lethal
VTA. For example, in a study of more than 24,000 SCDs,
Arntz et al. (2) observed a nadir of events between 12 AM
and 6 AM with a striking increase in events between 6 AM
and 12 PM as well as a nadir on Sundays and greater event
rate on Mondays. Similar distributions were reported in
patients with implantable cardioverter-deﬁbrillators (ICDs),
which provide superior temporal precision and arrhythmia
accuracy (3).See page 2702The mechanisms for the diurnal variations have not been
established. Exogenous factors such as physical activity or
mental stress that could stimulate sympathetic activity or
cause ischemia were suggested to account for the morning
peak and increase in events on Mondays. True circadian
rhythms are governed by biological clocks driven by a
transcription-translation feedback mechanism that takes
approximately 24 h. Biological clocks are composed of a
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the hypothalamus and synchronized to the environment by
light and other exogenous factors. The many processes
affected by biological clock activity result in a vast array of
permutations by which diurnal variations in arrhythmias
could occur. Most explanations involve indirect effects on
tissue electrophysiology related to autonomic activity or
ischemia (2,3). Cellular electrophysiological changes that
could account for diurnal variability of VTA due to direct
regulation of membrane ion channels by biological clocks
have been shown. Jeyaraj et al. (4) studied mice placed
in constant darkness and conﬁrmed that heart rate, QTc
interval, and cardiac expression of the alpha subunit for
the transient outward potassium current (Ito), Kv4.2
(encoded by Kcnd2), and the regulatory beta subunit, po-
tassium channel interacting protein 2 (KChIP2) (encoded
by Kcnip2), exhibit circadian rhythmicity, as do compo-
nents of the biological clock in the heart. New was the
discovery that the biological clock regulates KChIP2 by the
circadian oscillation of Krüppel-like factor 15 (Klf15), a
member of the family of Krüppel-like transcription factors
(4). KLF15 also inﬂuences cardiac remodeling, ﬁbrosis, and
myocyte hypertrophy in response to stress (4). Circadian
variation of potassium channel density and the associated
lengthening and shortening of repolarization duration and
refractoriness will alter the propensity for reentrant ar-
rhythmias, particularly when the change increases disper-
sion of refractoriness. Schroder et al. (5) demonstrated
regulation of the sodium channel gene (Scn5a) by the
biological clock of the cardiomyocyte in rodents. Muta-
tions of Scn5a are responsible for pathologic cardiac
phenotypes such as the congenital long QT syndrome
type 3, Brugada syndrome, and progressive cardiac con-
duction disorders. Oscillation of Scn5a transcription
could precipitate arrhythmias in vulnerable tissue due to
rhythmic variation of conduction velocity, refractoriness,
excitability, or automaticity. Although the relevance of
ﬁndings in rodents to human disease is a major question,
the evidence points to several mechanisms for periodic
variation of cardiac electrophysiology that could help
explain the temporal distribution of VTA.
Although it is known that not all arrhythmias exhibit the
classic diurnal variation, Patton et al. (6) report in this issue
of the Journal that a large and important group of patients
who receive ICDs do not show the phenotype expected
from previous studies (2,3). They examined the timing of
appropriate ICD interventions from SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial), a primary preven-
tion trial in which patients with heart failure and a low
ejection fraction (<36%) were randomized to placebo,
amiodarone, or an ICD (6). This analysis was driven by
3 hypotheses. The ﬁrst was that more than 25% of the
VTA episodes would occur between 6 AM and 12 PM
(representing 25% of the day), as expected on the basis
of previous reports (2,3). A total of 714 appropriate
ICD therapies for VTA occurred in 186 subjects. The
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2710proportion of VTA events occurring between 6 AM and
12 PM was only 20.7%. The per-patient analysis, which was
adjusted for the variation in the number of episodes of
VTA and provided equal weight to each patient, showed a
VTA frequency of only 21.3%. Therefore, the hypothesis
was rejected. Subgroup analysis of ischemic versus non-
ischemic etiology, age older than or younger than 50 years,
New York Heart Association (NYHA) functional class,
and use of beta-blockers did not identify a subgroup with a
signiﬁcant morning peak of VTA.
The second hypothesis, that the proportion of ICD
therapies occurring between 12 AM and 6 AM would be
signiﬁcantly below the 25% threshold, was supported by
the ﬁnding that the mean weighted frequency was 21%;
however, the signiﬁcance of the difference was marginal
(p ¼ 0.048, one-sided test). Subgroup analysis showed that
patients with ischemic cardiomyopathy, NYHA functional
class II, older than 50 years, or not on beta-blocker therapy
had events occurring during this interval that were also
signiﬁcantly less than 25%, with a weighted frequency
range of 17% to 19%. Conversely, patients with non-
ischemic cardiomyopathy, NYHA functional class III,
younger than 50 years, or on beta-blocker therapy at baseline
had weighted frequencies that were not signiﬁcantly less
than 25%, with adjusted event frequencies of 22.6% to
29.0%. Furthermore, instead of the marked increase in
event rate seen in the transition from the 12 AM to 6 AM
period to the 6 AM to 12 PM period in previous studies,
Patton et al. (6) observed that the event rate remained low
until 12 PM (2,3).
The hypothesis that the proportion of therapies on
Mondays would be greater than one-seventh (14.3%)
was also not supported. The only subgroup with a signiﬁ-
cantly higher event rate on Mondays was patients not on
beta-blocker therapy at baseline (mean weighted frequency
of 22%; p ¼ 0.029, one-sided test). Although the in-
vestigators did not test for a nadir in Sunday events, ex-
amination of the data provided show that event rates on
Sundays were lower than that on Mondays but similarly low
on Thursdays.
The analysis of Patton et al. (6) was not a prespeciﬁed
analysis of the original SCD-HeFT and therefore might be
considered hypothesis generating rather than hypothesis
testing. On the other hand, several features of the study
enhance the reliability of the observations. The rigorous
enrollment criteria of SCD-HeFT ensured relative homo-
geneity with respect to severity of structural heart disease
and depressed heart function as well as absence of a history
of sustained VTA or cardiac arrest. In addition, there was
prospective data collection, uniform ICD programming, and
independent tachyarrhythmia event adjudication. It was
appropriate for the authors to use one-sided statistical
testing because this increases the sensitivity of agreement
with previous studies. However, with respect to the failure
to reject the null hypothesis for a nocturnal nadir in VTA
events and a higher Monday event rate in a single subgroup,it should be recognized that one-sided testing increases the
probability of a type I error.
Many explanations could be posited for the absence of a
circadian distribution of VTA in the SCD-HeFT ICD pa-
tients. Potential inﬂuences include underlying cardiac disease,
past and current therapy, and lifestyle factors. The severity of
heart disease was likely greater (mean left ventricular ejection
fraction of 20%; 36% were NYHA functional class III) in
SCD-HeFT patients because previous studies did not exclude
patients withminimal structural heart disease (2,3,6). The use
of neuroendocrine antagonists and lipid-lowering drugs was
likely greater in SCD-HeFT (56% on beta-blockers, 94% on
renin angiotensin system inhibitors, and 34% on statins). No
information is available for comparison of work and lifestyle
variables. If it is argued that adrenergic and renin-angiotensin
system antagonist therapy reduced the diurnal inﬂuence of
sympathetic activity and that aggressive revascularization and
anti-ischemic and antiplatelet therapy reduced diurnal varia-
tion due to ischemia, an alternative explanation for persistent
VTA is necessary.
Disruption of the biological clock could plausibly link car-
diomyopathy, arrhythmias, and loss of diurnal variation of ar-
rhythmias. A germline knockout mouse of the core clock gene,
brain and muscle Arnt-like protein 1 (Bmal1), was associated
with stretch-induced arrhythmias and development of dilated
cardiomyopathy (5). Cardiomyocyte-speciﬁc deletion of Bmal1
was associated with loss of circadian variation of the sodium
channel gene (Scn5a), reduced functional expression of Scn5a,
and arrhythmia susceptibility (5). Deﬁciency or excess of the
clock-dependent oscillator Klf15 caused abnormal repolariza-
tion and enhanced susceptibility to ventricular arrhythmias and
loss of the circadian variation of QTc interval (4). It is notable
that KLF15 is also a transcriptional inhibitor of cardiac hyper-
trophy, ﬁbrosis, and structural remodeling. Although these
ﬁndings in animal models are of uncertain relevance to human
disorders, they indicate a potential mechanistic link between
persistent VTA, loss of circadian variation in arrhythmia events,
and possible inhibition of reverse remodeling in patients
enrolled in SCD-HeFT. It might be fruitful to examine other
signs of altered biological clock function in patients with SCD-
HeFT characteristics and determine if reverse remodeling of
clock functions can be shown. Better understanding of the links
between biological clocks and VTAmay open new avenues for
identifying and treating patients at risk for SCD.
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